Cytek Biosciences, Inc. (CTKB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Cytek Biosciences reported a 3% year-over-year unit growth for its core Full Spectrum Profiling (FSP) instruments, significantly outperforming a contracting flow cytometry market. The company emphasized its pioneering FSP technology as the new industry standard, positioning it to capture substantial market share within the 50,000-unit installed base, where only approximately 3,000 are currently FSP. Despite ongoing funding pressures in U.S. and EMEA academic sectors, Cytek is experiencing robust growth in Asia Pacific and projects continued expansion in its high-margin service and reagent businesses, which both grew 18% year-over-year. Management expressed confidence that strong recurring revenue and Asia Pacific performance will drive future top-line growth, leading to substantial EBITDA margin expansion due to high incremental instrument margins once broader market headwinds subside.

Analysis

Cytek Biosciences (CTKB) is demonstrating notable resilience and market share gains within a challenging life sciences capital equipment market. While the broader flow cytometry market contracted by 3% in Q2, Cytek reported a 3% year-over-year unit growth for its core Full Spectrum Profiling (FSP) instruments. Management attributes this outperformance to its pioneering FSP technology, which is becoming the industry standard and creating a significant competitive moat. The company is poised to capitalize on a large replacement cycle, with only an estimated 3,000 of the 50,000-unit global installed base currently utilizing FSP technology. Geographically, performance is bifurcated; robust growth in Asia-Pacific, which grew approximately 9% in the first half and is benefiting from strong government support in China, is offsetting weakness in the U.S. and EMEA. The U.S. academic market shows signs of stabilization, while EMEA remains under pressure from government budget reallocations. A key growth vector is the high-margin recurring revenue stream, with both services and reagents growing at 18% year-over-year. The company is capturing less than 10% of an estimated $150 million annual reagent opportunity on its own installed base, indicating substantial runway for growth. Management projects that once headwinds in U.S. and EMEA instrument sales abate, the company's high incremental instrument margins (75-80%) will drive significant EBITDA margin expansion, unlocking substantial operating leverage.

Key Decisions for Investors

• Investors should recognize Cytek's outperformance in a contracting market as a sign of strong technological leadership and consider that the large, underpenetrated FSP replacement cycle provides a compelling long-term growth thesis.
• Monitor instrument sales in the U.S. and EMEA, as a recovery in these regions would act as a powerful catalyst for accelerated top-line growth and trigger the company's significant operating leverage, leading to rapid EBITDA margin expansion.
• Closely track the growth rate of the high-margin recurring revenue from services and reagents, as continued success in capturing a larger share of the reagent spend on its installed base can de-risk the investment profile and provide a more stable foundation for valuation.
• Acknowledge the geographic concentration risk, as current growth is heavily dependent on the Asia-Pacific market, and remain aware of geopolitical factors and funding environments in key regions like China and Europe which could impact future performance.